Published in:
Open Access
01-12-2015 | Oral presentation
O068. A 2 years prospective evaluation study on onabotulinumtoxinA 195 U in chronic migraine
Authors:
Andrea Negro, Lidia D'Alonzo, Noemi Lala, Paolo Martelletti
Published in:
The Journal of Headache and Pain
|
Special Issue 1/2015
Login to get access
Excerpt
OnabotulinumtoxinA (Botox®) is the first and so far the only treatment to receive a specific license for prevention of chronic migraine (CM). In our Headache Clinic the therapy with onabotulinumtoxinA is routinely administered to CM patients on a daily basis since 2001. Preventive treatment with onabotulinumtoxinA was offered to all patients that were 1) adults; 2) fulfilling the ICHD-II criteria for CM with or without analgesic overuse; and 3) with contraindications or lack of efficacy or tolerability to other preventive drugs. …